

ESE: The Voice for Endocrinology

ESE's Mission Statement - 'Shaping the Future of Endocrinology' - requires that we actively engage with different stakeholders in creating a European and broader international environment that recognises the important place of 'endocrine' health in the development of future health care policies and support to research programmes.

In late 2018, ESE conducted a large survey to map the current status of endocrinology in Europe, and to prioritize the themes that matter most for the future of endocrinology and would benefit from outreach to European decision makers. More than 3 100 endocrine professionals responded to the survey, and a summary of the findings can be found [HERE](#).

The Policy and Advocacy activities of ESE focus on three areas that are of strategic importance to the European and global health care agenda:

- Achieving greater health care effectiveness and resilience through health promotion and disease prevention, with specific focus on the post COVID-19 recovery and impact on and from endocrine and metabolic diseases. This applies to both prevalent and rare diseases.
- Supporting the Cancer Mission, provide input to the 'Beating Cancer Plan' and stimulate research with a focus on the endocrine origins and consequences
- Engage in EU debates around climate change and environment with a focus on endocrine disruptors

To steer ESE's Policy and Advocacy activities ESE has created in 2019 a P&A Task Force. The remit and composition of this task force can be found [here](#). The composition of the Task Force reflects a number of different stakeholders in the policy and advocacy efforts, including National Societies, the ESE Council of Affiliated Societies, endo-ERN and specific Expert Groups like the EDC expert panel.

Our stakeholders also include our industry corporate members. At the Industry Partnership Board and our Premium Corporate Members (Ipsen, Pfizer, Recordati Rare Diseases and Takeda) policy and advocacy is a strategic agenda topic, looking for areas of mutual interest and cooperation.

To reinforce ESE's activities in the European policy environment, ESE has [established a presence](#) in Brussels and has engaged more recently also the services of Hill + Knowlton Strategies (Brussels Office), an international public relations agency.

Policy and Advocacy is our approach to get the European endocrinology voice heard by policy makers and other external stakeholders.

If you want to know more or have an interest to become engaged in our activities, please complete [this form](#). The ESE office will be happy to connect with you and discuss your specific interests.

ESE – the Voice for Endocrinology

For more information, also contact:

Dirk De Rijdt, ESE Director of Strategic Partnerships, dirk.de-rijdt@ese-hormones.org

Mischa Van Eimeren, ESE EU Liaison Officer, mischa.vaneimeren@esehormones.org

European Society of Endocrinology

Starling House, 1600 Bristol Parkway North, Bristol, BS34 8YU, UK Tel +44 1454 642247 info@euro-endo.org www.ese-hormones.org

President **Andrea Giustina** Milan, Italy. President-elect **Martin Reincke** Munich, Germany. Secretary **Mónica Marazuela** Madrid, Spain. Treasurer **Bulent Yildiz** Ankara, Turkey. Executive Committee members: **Felix Beuschlein** Munich, Germany. **Simona Glasberg** Jerusalem, Israel. **Riccarda Granata** Torino, Italy. **Beata Kos-Kudła** Katowice, Poland. **Robin Peeters** Rotterdam, The Netherlands. **Camilla Schalin-Jääntti** Helsinki, Finland. Ex-Officio members: Nurse Representative **Sherwin Criseno** West Bromwich, UK. ECAS Representative **Djuro Macut** Belgrade, Serbia. EYES Representatives **Ljiljana Marina** Belgrade, Serbia and **Ayse Zengin**, Victoria, Australia.

Registered in England and Wales No. 5540866. Registered Office: Redwood House, Brotherswood Court, Great Park Road, Almondsbury Business Park, Bradley Stoke, Bristol, BS32 4QW, UK. Company Limited by Guarantee. Registered Charity No. 1123492.